Abstract 51Characterization of FOLH1 Expression in Renal Cell Carcinoma Eric Ovruchesky, Elizabeth Pan, Andrew Elliott, Shankar Siva, Praful Ravi, Brad McGregor, Toni Choueiri, Aditya Bagrodia, Ithaar Derweesh, Pedro Barata, Elisabeth I. Heath, Emmanuel Antonarakis, Sourat Darabi, David Hoon, Amir Mortazavi, Phillip Walker, Chadi Nabhan, Shuanzeng Wei, Rana R. McKay
Ivy Riano: Tips to advise on how to plan your ASCO annual meeting / ASCO, ASCO Annual Meeting, cancer, Dartmouth-Hitchcock, early career oncologists, Ivy
Ivy Riano: Tips to advise on how to plan your ASCO annual meeting / ASCO, ASCO Annual Meeting, cancer, Dartmouth-Hitchcock, early career oncologists, Ivy
Don’t miss out on an engaging Tweetorial by Florez Lab and Young Lung Cancer Initiative / cancer, Florez Lab, Lung cancer, OncoDaily, Oncology, tweetorial,
Toni Choueiri: The February ASCO Plenary Series are here / ASCO, ASCO Plenary Series, cancer, DREAMM-7, FRUTIGA, gastric/GE junction adenocarcinoma,
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive…
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive…
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive…
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive…
Dr. Nazli Dizman has traveled across the world to pursue her passion for clinical and translational cancer research and further her career as a medical…
KCRS23 is taking place in Boston! Join us as we continue to collaborate, share innovations, and discuss research progress.You can register NOW for the virtual component…
